The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:6/17/2018
Start Date:October 2016
End Date:December 2020
Contact:Dana Leach, PhD
Email:Dana.Leach@medicine.ufl.edu
Phone:352-273-8944

Use our guide to learn which trials are right for you!

Characterize the Gut Microbiota in Subjects With Heart Failure and Pre-heart Failure With Preserved Ejection Fraction

Gut microbiota play an important role in normal cardiovascular function and pathophysiology
of cardiovascular diseases. Patients with heart failure (HF) have substantial hemodynamic
changes which lead to intestinal hypoperfusion and congestion and eventually change gut
morphology, permeability, function and composition of gut microbiota and cause translocation
of microbial and endotoxins into the blood stream. Additionally, metabolites derived from gut
microbiota modulate the pathophysiology of HF. Patients with HF have intestinal overgrowth of
pathogenic bacteria and increased gut permeability. Accumulating evidence demonstrates that
antibiotic treatment benefits patients with acute coronary syndromes and reduces the
incidence of ischemic cardiovascular events. Taking the strong association of gut microbiota
with HF into account, it is reasonable to speculate that gut microbiota could contribute to
the progression of pre-HF with preserved ejection fraction (pre-HFpEF) to HF with preserved
ejection fraction (HFpEF). Pre-HFpEF remains poorly understood, yet has high prevalence and a
significantly high risk for death in comparison to patient without pre-HFpEF. We hypothesize
that altered gut microbiota is involved in the initiation and establishment of HF and
pre-HFpEF.

The research study will initially enroll 50 subjects without HF as normal controls,120
subjects with history of HF and 50 subjects with pre-HFpEF to characterize gut microbiota.
The subjects will provide blood samples and a stool sample.

Inclusion Criteria:

- Competent and willing to provide consent

- Control subjects with normal heart function

- Subjects with history of HF

- Subjects with impaired ventricular relaxation and/or elevated left ventricular end
diastolic pressure measured by echocardiography and/or catheterization, yet has not
had HF clinical presentations

Exclusion Criteria:

- intestinal surgery,

- inflammatory bowel disease,

- celiac disease,

- lactose intolerance,

- chronic pancreatitis or

- other malabsorption disorder
We found this trial at
1
site
Gainesville, Florida 32610
Phone: 352-273-8944
?
mi
from
Gainesville, FL
Click here to add this to my saved trials